Table 4 Exacerbations and hospitalizations
Variable | Patients treated with AVAPS | Control group | Treatment Effect (95% CI) 6 months–baseline | P-value | ||
|---|---|---|---|---|---|---|
6 months before inclusion | Study period (6 months after AVAPS start) | 6 months before inclusion | Study period (6 months after BiPAP start) | |||
Exacerbation (n) | 2.7 ± 1.7 | 1.5 ± 0.3 | 2.6 ± 1.9 | 1.5 ± 0.2 | −0.9 (− 0.9 to 0.7) | 0.213 |
Hospitalization (n) | 3.2 ± 1.1 | 1.1 ± 0.1 | 3.5 ± 1.3 | 1.2 ± 0.1 | −0.1 (− 0.6 to 0.4) | 0.342 |
Hospital days(n) | 5.2 ± 2.1 | 3.4 ± 2.1 | 5.3 ± 2.2 | 3.5 ± 2 | − 1.5 (− 5 to 2) | 0.321 |